Psoriatic Arthritis

Roy Fleischmann, MD, examined the necessity of performing repeated x-rays in patients with rheumatic disease as a part of disease management.

Guselkumab, an interleukin-23 inhibitor, demonstrated sustained improvements in both TNF-naïve and TNF-experienced patients with psoriatic arthritis.

In this Q&A, Rubén Queiro, MD, PhD, discussed the findings of a study that evaluated the retention rate and safety of ixekizumab in patients with psoriatic arthritis in real clinical practice conditions.

While high-sensitive Troponin T (hsTnT) is primarily used as a marker of heart disease, data suggests its potential as a useful marker of inflammation in the joints.

Adult patients with psoriatic arthritis starting a second-line biological after discontinuing a TNF were enrolled in the nationwide cohort study.

An analysis of data from 4 phase 2/3 studies provides insight into the effects of guselkumab in psoriatic arthritis based on whether or not a person had prior exposure to TNF inhibitor therapy.

Secukinumab therapy was associated with inhibition of joint tenderness and swelling, but high baseline radiographic damage was associated with reduced likelihood of full inhibition.

An interview segment with Armstrong in which she elaborates on some of the main points made from her presentation on psoriasis treatments.

Patients with psoriatic arthritis who achieve minimal disease activity during the first year of diagnosis are shown to experience better health-related quality of life, improved mental wellbeing, and reduced fatigue.

Although the incidence rates were similar among those treated with TNFi and biologics-naïve patients, patients with psoriatic arthritis had a 35% increased risk when compared with the general population.

Results from the MUST trial reported that ustekinumab monotherapy was just as effective in treating psoriatic arthritis as treatment with ustekinumab plus methotrexate.

The results imply the possibility of improving patient stratification based on both clinical and immune cellular phenotypes.

A comparative trial of biologic agents suggest IL-17A inhibitors may more significantly improve skin clearance in comorbid patients.

Take 5 minutes to catch up on Rheumatology Network's highlights from the week ending December 17, 2022.

The results suggest a basis for clinicians to detect the earlier potential development of psoriasis, psoriatic arthritis, and Crohn’s disease.

“Respiratory tract infections constitute the most common infections in patients with rheumatic diseases, especially under immunosuppressive treatment,” investigators explained.

Identifying the current prevalence and effect of fatigue on patients with psoriatic arthritis may lead to new strategies designed to manage this commonly-reported symptom.

Holding methotrexate after the second COVID-19 vaccine dose is associated with similar immunogenicity and a lower risk of disease flare compared with withholding methotrexate after both vaccine doses.

DISCOVER-2 is a phase 3, randomized, double-blind, multicenter study assessing the safety and efficacy of subcutaneous guselkumab treatment in biologic-naïve patients with active PsA.

“The data continue to validate our hypothesis that izokibep offers differentiated efficacy with high potency and small size and reinforces izokibep’s potential to manage the hard-to-treat manifestations of PsA."

Nowell emphasized that simple changes, such as targeted walking goals and meditative breathing, are low energy and low cost, yet extremely effective.

“There's a real interest and need for wellness programs out there among people living with psoriatic arthritis. This is something that matters to them even more now living with a chronic disease.”

Deucravacitinib showed sustained efficacy in the various outcomes in psoriatic arthritis and a unique and consistent safety profile.

In this Q&A, Fabian Proft, MD, discussed the findings of his study that evaluated the DAPSA using a quick quantitative C reactive protein assay (Q-DAPSA) in patients with psoriatic arthritis.

Two methods of identifying patients with axPsA, including an artificial intelligence approach, reported nearly identical outcomes with positive improvement of symptoms of axPsA.